Pharmaceuticals
Juniper Biologics Pte. Ltd. signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
LUGANO, Switzerland, Sept. 1, 2022 /PRNewswire/ -- Helsinn Group ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company foc...
2022-09-01 17:00
2405
"Blue Pea Flower and Banana Stem Extract" Drink to Reduce the Risk of Urinary Stone - Another Medical Innovation from Chula MED
BANGKOK, Sept. 1, 2022 /PRNewswire/ -- Urinary tract stone is common among
people of the tropics such asThailand. In 2020, surveys show that 16-17 percent
of the population have this disease, and up to 12 percent of the patients have
an asymptomatic urinary stone.
2022-09-01 13:11
5046
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
Addition increases diversity of Board governance and supports further
independent expertise
DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences
2022-09-01 07:30
4275
Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet pat...
2022-08-31 21:00
3601
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting th...
2022-08-31 17:05
2753
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is to asses...
2022-08-31 12:24
2573
GC Biopharma and Speragen Sponsored an Externally Led - Patient Focused Drug Development with FDA Attendance
YONGIN, South Korea and AUSTIN, Texas, Aug. 30 2022 /PRNewswire/ -- GC Biopharma (006280.KS) and Speragen today announced that a joint Externally Led - Patient-Focused Drug Development (EL-PFDD) meeting hosted by SSADH Association and attended by the U.S. FDA and other stakeholders was held to a...
2022-08-31 08:33
2849
Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area
NANNING, China, Aug. 31, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by Guangxi Yizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic & Technological Development Area ("Area") has been granted the registration certificate of class ...
2022-08-31 00:32
3142
LifeTech Scientific Corporation (1302.HK) Announces 2022 Interim Results
* Revenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items SHENZHEN, China, Aug. 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally ...
2022-08-30 21:45
5587
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
* Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B * Lemzoparlimab is on track for Phase 3 study for 1L MDS * Amendment to the global partnership with AbbVie for certain new CD47 antibodies currently in developm...
2022-08-30 18:00
3225
'Medlab Asia & Asia Health 2022' to Promote Thailand as a Medical Hub of ASEAN by Collaborating with Department of Health Service Support and Medical Industry
BANGKOK, Aug. 30, 2022 /PRNewswire/ -- 'Medlab Asia & Asia Health 2022' is the leading medical event in the ASEAN region which is all set to run in Thailand for the first time, co-hosted by IMPACT Exhibition Management and Informa Markets, and supported by Department of Health Service Support, Mi...
2022-08-30 15:35
3121
Kintor Announces 2022 Interim Results and Recent Business Update
SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma" or "the Company", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results and released an update on i...
2022-08-30 00:19
4404
NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER
* H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and high selectivity against multiple EGFR mutations including those with EGFR C797S mutation. * RedCloud Bio has initiated H002 Phase I/IIa clinical studies in both China and US. SHANGHAI, Aug. 29, 20...
2022-08-29 19:30
2865
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock ...
2022-08-29 15:59
4236
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress
* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. * Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization. * The novel adjuvants vaccine will create a strong growth engine. TAIZHOU, China, ...
2022-08-29 13:08
5202
Fosun International Listed in Forbes 2022 China ESG 50
HONG KONG, Aug. 29, 2022 /PRNewswire/ -- Forbes China recently released its "2022 China ESG 50" list. Fosun International has been included on the list for its outstanding ESG performance and its active contribution to the fight against the COVID-19 pandemic.Forbes China pointed out that ESG is s...
2022-08-29 12:52
5007
Porton Advanced and Royaltech Announce Strategic Collaboration to Accelerate the Development of Bacterial Drugs and mRNA Drugs
SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions. (hereinafter referred to as Porton Advanced) announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. (hereinafter referred to as Suzhou Royaltech).This strategic collaboration will further in...
2022-08-29 12:23
2813
Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation
SHANGHAI, Aug. 27, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. (Sanyou) and Shanghai KangaBio Co., Ltd. (KangaBio) have reached an antibody drug licensing agreement, regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an e...
2022-08-28 08:00
4630
Ascentage Pharma Announces 2022 Interim Results
SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting p...
2022-08-27 00:47
15821
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization
BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic prod...
2022-08-26 22:09
13195
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 306 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
36178
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
35193
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
33953
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
28486
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
2026-10-21 15:00
16480